-
1 Comment
Kilitch Drugs (India) Limited is currently in a long term uptrend where the price is trading 47.6% above its 200 day moving average.
From a valuation standpoint, the stock is 56.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.1.
Kilitch Drugs (India) Limited's total revenue rose by 27.6% to $203M since the same quarter in the previous year.
Its net income has increased by 134.3% to $22M since the same quarter in the previous year.
Finally, its free cash flow grew by 784.5% to $365M since the same quarter in the previous year.
Based on the above factors, Kilitch Drugs (India) Limited gets an overall score of 5/5.
| ISIN | INE729D01010 |
|---|---|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Exchange | NSE |
| CurrencyCode | INR |
| Target Price | 466 |
|---|---|
| PE Ratio | 20.48 |
| Market Cap | 6B |
| Beta | -0.19 |
| Dividend Yield | None |
Kilitch Drugs (India) Limited engages in the development and operation of pharmaceutical business in India, Asia, Africa, Latin America, and Commonwealth of Independent States. The company offers various parenteral, nasal, and topical products, such as liquid ampoules, vials, dry powder injectables, and metered nasal drops for gastroenterology, non-steroidal anti-inflammatory, anticonvulsant/antiepileptic, anti-inflammatory, anti-malarial, aminoglycoside, antibacterial, anti-hypertensive, anti-infective, diagnostic, sympathomimetic, local anesthetic, neurotonic, uterine stimulant, external preparation, anticoagulant, narcotic, oncology, ophthalmic, antifungals, corticosteroids, and other drugs, as well as vaccines and veterinary products, iron supplements for anemia, Klavmox, and Onecef. It also provides oral solid dosage formulations, including tablets, capsules, dry syrup, and oral powder for antibiotics, anti-diabetics, cardiovascular, and other areas; effervescent tablets and powders, such as Roipar, Duregra, and Roivit; and nutritional products comprising Celtine. In addition, the company offers cosmetics, which include oil, lotion, liquid to cream, paste in skin, and personal and hair care; herbal products used for sore throat, prostate problems, and as a supplement for diabetes, obesity, libido, and other conditions; ortho rehabilitation and implants; and medical device comprising C-Seal, a skin adhesive to hold closely approximated skin edges without marks of sutures and incisions. Further, it provides PH-7 which reduces stomach acid; SRO kit for treating childhood diarrhea; 9-Vit used in surgery, extensive burns, fractures, and other trauma; and HPure for sore throat and cough. The company exports its products. Kilitch Drugs (India) Limited was founded in 1978 and is headquartered in Mumbai, India.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for KILITCH.NSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
